Compugen to Present at Single Cell Genomics 2024 Conference
Compugen (Nasdaq: CGEN) will present at the Single Cell Genomics 2024 conference in Greece from September 16-18, 2024. Dr. Roy Granit, Head of Computational Discovery, will showcase a poster on applying AI to gain insights into the novel immune checkpoint PVRIG through single-cell and spatial transcriptomics.
The presentation highlights additional biological insights generated using Compugen's AI/ML-powered computational discovery platform, UnigenTM. These findings support the potential of PVRIG inhibition to induce anti-tumor activity in indications previously resistant to immunotherapy, differentiating it from other immune checkpoints.
The poster presentation, titled 'Applying AI to Gain Insights into the Novel Immune Checkpoint PVRIG Through Single-Cell and Spatial Transcriptomics,' is scheduled for Monday, September 16, 2024. It will be available on Compugen's website following the presentation.
Compugen (Nasdaq: CGEN) presenterà al convegno di Genomica a Cellule Singole 2024 in Grecia dal 16 al 18 settembre 2024. Il Dr. Roy Granit, Responsabile della Scoperta Computazionale, mostrerà un poster sull'applicazione dell'IA per ottenere informazioni sul nuovo checkpoint immunitario PVRIG attraverso la trascrittomica a cellule singole e spaziale.
La presentazione evidenzia ulteriori approfondimenti biologici generati utilizzando la piattaforma di scoperta computazionale potenziata dall'AI/ML di Compugen, denominata UnigenTM. Questi risultati supportano il potenziale dell'inibizione di PVRIG di induzione di attività anti-tumorale in indicazioni precedentemente resistenti all'immunoterapia, distinguendolo da altri checkpoint immunitari.
La presentazione del poster, intitolata 'Applicare l'IA per Ottenere Approfondimenti sul Nuovo Checkpoint Immunitario PVRIG Tramite Trascrittomica a Cellule Singole e Spaziale,' è programmata per lunedì 16 settembre 2024. Sarà disponibile sul sito web di Compugen dopo la presentazione.
Compugen (Nasdaq: CGEN) presentará en la conferencia de Genómica de Células Individuales 2024 en Grecia del 16 al 18 de septiembre de 2024. El Dr. Roy Granit, Jefe de Descubrimiento Computacional, mostrará un póster sobre la aplicación de la IA para obtener información sobre el nuevo punto de control inmunitario PVRIG a través de la transcriptómica de células individuales y espaciales.
La presentación destaca información biológica adicional generada utilizando la plataforma de descubrimiento computacional impulsada por AI/ML de Compugen, denominada UnigenTM. Estos hallazgos respaldan el potencial de la inhibición de PVRIG para inducir actividad anti-tumoral en indicaciones que previamente eran resistentes a la inmunoterapia, diferenciándolo de otros puntos de control inmunitarios.
La presentación del póster, titulada 'Aplicando IA para Obtener Información sobre el Nuevo Punto de Control Inmunitario PVRIG a Través de la Transcriptómica de Células Individuales y Espaciales,' está programada para el lunes 16 de septiembre de 2024. Estará disponible en el sitio web de Compugen después de la presentación.
컴퓨젠 (Nasdaq: CGEN)은 2024년 9월 16일부터 18일까지 그리스에서 열리는 단일 세포 유전체학 2024 콘퍼런스에서 발표할 예정입니다. 로이 그라닛 박사, 컴퓨테이셔널 발견 부서장,은 단일 세포 및 공간 전사체학을 통해 새로운 면역 체크포인트 PVRIG에 대한 통찰력을 얻기 위해 AI를 적용한 포스터를 선보일 것입니다.
이 발표에서는 컴퓨젠의 AI/ML 기반 컴퓨테이셔널 발견 플랫폼인 UnigenTM을 활용하여 생성된 추가 생물학적 통찰력도 강조됩니다. 이러한 발견은 PVRIG 억제가 면역 요법에 이전에 저항성이 있었던 질환에서 항종양 활동을 유도할 가능성을 뒷받침하여, 다른 면역 체크포인트와 차별화됩니다.
'단일 세포 및 공간 전사체학을 통한 새로운 면역 체크포인트 PVRIG에 대한 통찰력을 얻기 위해 AI를 적용하기'라는 제목의 포스터 발표는 2024년 9월 16일 월요일로 예정되어 있습니다. 발표 후 컴퓨젠 웹사이트에서 확인할 수 있습니다.
Compugen (Nasdaq: CGEN) présentera lors de la conférence de Génétique des Cellules Individuelles 2024 en Grèce, du 16 au 18 septembre 2024. Le Dr Roy Granit, Responsable de la Découverte Computationnelle, présentera un poster sur l'application de l'IA pour obtenir des informations sur le nouveau point de contrôle immunitaire PVRIG à travers la transcriptomique des cellules uniques et spatiales.
La présentation met en avant des insights biologiques supplémentaires générés grâce à la plateforme de découverte computationnelle alimentée par AI/ML de Compugen, appelée UnigenTM. Ces résultats soutiennent le potentiel de l'inhibition de PVRIG pour induire une activité anti-tumorale dans des indications qui étaient auparavant résistantes à l'immunothérapie, le distinguant des autres points de contrôle immunitaires.
La présentation du poster, intitulée 'Application de l'IA pour Obtenir des Insights sur le Nouveau Point de Contrôle Immunitaire PVRIG par le Biais de la Transcriptomique des Cellules Individuelles et Spatiales', est programmée pour le lundi 16 septembre 2024. Elle sera disponible sur le site web de Compugen après la présentation.
Compugen (Nasdaq: CGEN) wird auf der Konferenz für Einzelzellgenomik 2024 in Griechenland vom 16. bis 18. September 2024 präsentieren. Dr. Roy Granit, Leiter der computationalen Entdeckung, wird ein Poster zur Anwendung von KI zur Gewinnung von Erkenntnissen über den neuartigen Immun-Checkpoint PVRIG durch Einzelzell- und räumliche Transkriptomik vorstellen.
Die Präsentation hebt zusätzliche biologische Erkenntnisse hervor, die mithilfe von Compugens KI/ML-gestützter Plattform für computationale Entdeckung, UnigenTM, generiert wurden. Diese Ergebnisse unterstützen das Potenzial der PVRIG-Hemmung zur Induktion von antitumoraler Aktivität bei Indikationen, die zuvor gegen Immuntherapien resistent waren, und heben es von anderen Immun-Checkpoint ab.
Die Posterpräsentation mit dem Titel 'Anwendung von KI zur Gewinnung von Erkenntnissen über den neuartigen Immun-Checkpoint PVRIG durch Einzelzell- und räumliche Transkriptomik' ist für Montag, den 16. September 2024, geplant. Sie wird nach der Präsentation auf der Website von Compugen verfügbar sein.
- None.
- None.
HOLON,
Additional biological insights characterizing the uniqueness of the novel immune checkpoint PVRIG discovered by Compugen, were generated using Compugen's AI/ML-powered computational discovery platform, recently branded as UnigenTM. The data further support previous findings that PVRIG inhibition may be differentiated from other immune checkpoints and may have the potential to induce anti-tumor activity in indications previously refractory to immunotherapy.
Poster presentation details:
Poster title: Applying AI to Gain Insights into the Novel Immune Checkpoint PVRIG Through Single-Cell and Spatial Transcriptomics
Poster number: 40
Presenter: Roy Granit, Ph.D., Head of Computational Discovery, Compugen Ltd.
Date: Monday, September 16, 2024
The poster will be available on the publications section of Compugen's website, www.cgen.com, following presentation.
About Unigen™
Compugen has been at the forefront of decoding cancer biology, with its AI/ML powered predictive computational discovery platform, recently branded as Unigen™. Unigen™ is Compugen's code-to-cure, flexible-loop platform for the computational prediction of novel drug target discovery and development of cancer immunotherapy. Unigen™ combines Compugen's deep scientific knowledge, AI/ML predictive algorithms and a cloud-based, technology-agnostic platform integrating a variety of biological data such as multi-omics, single-cell RNA sequencing and spatial omics data. The outcomes from Compugen's preclinical and clinical trials enrich the proprietary knowledgebase to discover additional novel drug targets and further understand complex biology. To date, Unigen™ has yielded multiple novel immuno-oncology drug targets, potential first- or best-in-class clinical stage immuno-oncology programs, validating partnerships with multiple pharmaceutical companies and undisclosed programs in its early-stage pipeline.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (UnigenTM) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which has been granted IND clearance from the FDA, is licensed to Gilead. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
VP, Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-present-at-single-cell-genomics-2024-conference-302241834.html
SOURCE Compugen Ltd.
FAQ
What is Compugen presenting at the Single Cell Genomics 2024 conference?
When and where is the Single Cell Genomics 2024 conference taking place?
Who is presenting the poster for Compugen (CGEN) at the conference?
What is UnigenTM in relation to Compugen's research?
What potential does PVRIG inhibition show according to Compugen's (CGEN) findings?
